New perspective in the management of neuroendocrine differentiation in prostate adenocarcinoma

International Journal of Clinical Practice
Alessandro SciarraFranco Di Silverio

Abstract

In this review, we will present some of the information that is known about neuroendocrine (NE) cells and differentiation in the prostate. We will then speculate on the potential role that NE differentiation in prostate carcinoma may play and how this differentiation may be clinically analysed and treated. The androgen-independent growth of prostate cancer can be caused by different mechanisms; one of these is receptor-specific paracrine or autocrine growth modulation of human prostatic cancer cells by neuropeptides secreted by NE cells. Our results affirm that different methods of androgen deprivation can influence the serum chromogranin A (CgA) levels to different extents in prostate cancer. In particular, bicalutamide produces a significantly lower increase in serum CgA compared with castration therapy. In the light of other evidence that supports a significant relationship between serum CgA levels, tissue CgA expression and NE activity, we hypothesise that bicalutamide may reduce the risk of NE cell hyperactivation in prostate cancer. It is important to determine whether increases in CgA levels and NE cell activation are associated with progression towards hormone-independent prostate cancer. We recently proposed as therapy...Continue Reading

References

Aug 1, 1991·The Journal of Urology·D KadmonP T Scardino
Dec 1, 1986·Pathology, Research and Practice·P A AbrahamssonL Grimelius
May 1, 1969·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·A G Pearse
Jan 1, 1994·Virchows Archiv : an International Journal of Pathology·S BattagliaA R Botticelli
Nov 1, 1993·Histochemistry·J L KrijnenT H van der Kwast
Jan 1, 1996·The Prostate. Supplement·P A Abrahamsson
Jul 3, 1996·Journal of the National Cancer Institute·C N RobertsonR L Fine
Mar 4, 1998·Journal of Clinical Laboratory Analysis·J T WuR A Stephenson
Feb 7, 2002·Expert Opinion on Investigational Drugs·Michael KoutsilierisDimitrios Karamanolakis
May 1, 2002·European Journal of Endocrinology·S W J LambertsL J Hofland
Jun 22, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M HejnaM Raderer

❮ Previous
Next ❯

Citations

Mar 13, 2009·European Journal of Nuclear Medicine and Molecular Imaging·Sara BelloliFerruccio Fazio
Sep 18, 2007·Medical Oncology·Victor ValdespinoPavel Pisa
Mar 10, 2012·Clinical Genitourinary Cancer·Deliu-Victor MateiOttavio de Cobelli
Nov 1, 2006·Prostate Cancer and Prostatic Diseases·E C NelsonC P Evans
Jun 2, 2007·The Anatomical Record : Advances in Integrative Anatomy and Evolutionary Biology·Ildefonso IngelmoLuis Santamaría
Oct 17, 2009·Industrial Health·Sanja KezicMaarten M Verberk
Sep 14, 2007·Scandinavian Journal of Urology and Nephrology·Kaoru Nemoto, Yuji Tomita

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.